Exosomes

What it actually is

Exosomes are extracellular vesicles roughly 30–150 nanometres across, released by most cell types. They carry proteins, lipids and RNA, and they are one of the ways cells signal to each other. The commercial pitch is that they deliver the useful signalling cargo of stem cells without the cells — no living material, no rejection risk, easier storage. The pitch is biologically reasonable. The evidence and the manufacturing are not yet there.

Where it comes from

Conditioned culture medium from a parent cell population, most often MSCs. Everything about the product therefore depends on the parent cells, the culture medium and the isolation method — all upstream variables the buyer usually never sees.

How it is made — and what can go wrong

Isolation is by ultracentrifugation, size-exclusion chromatography, precipitation or tangential-flow filtration, and the methods do not produce equivalent material. A preparation may contain vesicles of many sizes, protein aggregates, lipoproteins and medium components. The International Society for Extracellular Vesicles publishes the MISEV standards precisely because verifying what is in a vial is difficult even for specialist laboratories.

Regulatory status

On 6 December 2019 the FDA issued a public safety notification after patients in Nebraska suffered serious adverse events following treatment with unapproved products marketed as containing exosomes, derived from placental tissue. The FDA states there are no approved exosome products and that exosomes used to treat disease are regulated as drugs and biologics requiring premarket approval. In the EU an exosome product intended to treat disease falls under medicines law on the same logic.

What the evidence shows

Preclinical literature is large and genuinely interesting. Controlled human efficacy data is thin. Aesthetic and wellness marketing has run far ahead of the clinical record, and the gap between the two is currently the widest of any cell-derived product.

Limits worth knowing

Dose is not standardised — 'billions of exosomes' is a particle count, not a potency measure, and particle count does not establish biological activity. Sterility is a real hazard: the Nebraska cases were infections. Nothing about a cell-free label removes contamination risk.

What this could actually be used for

An exosome is not a cell. It is a 30–150 nm vesicle that a cell releases, carrying proteins, lipids and RNA. Nothing engrafts, nothing divides, nothing has to survive in the recipient. What is delivered is a package of signals, and once it is delivered the story ends.

That single property — cargo without a living cell — opens directions where putting a cell would be impractical, unsafe, or simply pointless because the cell would die before doing anything useful.

Skin and hair 19 studies registered

A follicle is small, dense and well supplied with blood. Signalling molecules can reach it topically or by microinjection, and nothing has to take up residence for a signal to land. The step being targeted is pushing a dormant follicle back into its growth phase. This is the most commercially active use and the least regulated one, which is why the marketing here runs furthest ahead of the evidence. All cell therapy research registered for this condition →

Brain and nerve injury 18 studies registered

Vesicles this small can in principle cross barriers that whole cells cannot, including the blood–brain barrier. The target is not the neurons already destroyed — those are gone — but the inflammatory cascade over the following days that kills a second wave of still-viable tissue. Success would look like a smaller final lesion, not a regrown brain. All cell therapy research registered for this condition →

Chronic wounds and inflammation 26 studies registered

A wound that will not close is usually stuck in its inflammatory phase rather than short of material. The proposed role is to push local signalling out of that stall and let normal healing resume, which is why the interest sits in diabetic ulcers rather than in fresh surgical wounds. All cell therapy research registered for this condition →

Joints 5 studies registered

The argument is that most of what an injected mesenchymal cell does in a joint is secreted anyway, so the vesicle fraction alone might reproduce the effect without a living cell to keep alive, ship cold, or match to a donor. All cell therapy research registered for this condition →

Acute lung injury

Inhaled or infused vesicles are studied where the problem is runaway inflammation in tissue too fragile to carry a cellular graft and too diffuse to inject.

Drug delivery

Outside regeneration entirely: the vesicle is used as an envelope for a drug that is otherwise hard to target. Here the exosome is packaging rather than medicine, and the therapeutic claim belongs to whatever is loaded inside it.

Where it stops. Everything above depends on what is actually inside the vesicle, which varies with the parent cell, the culture conditions and the purification method. Two products both labelled ‘exosomes’ can have almost nothing in common, and no label tells you which one you are being given.

What the registry actually shows for this cell type

Our own count of every study registered on ClinicalTrials.gov under this cell type, retrieved 2026-09-04. A registration is a declaration of intent, not a result — which is why the status column matters more than the total does.

Reading it: 29 studies stopped before finishing — terminated, withdrawn or suspended, 5% of the total; 378 studies carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine; 48 studies reached Phase 2 or later, against 147 studies still at Phase 1 or earlier; 128 records have not had a status update from the sponsor and may be dormant.

The directions above describe where the biology points and where research has been registered. They are not claims that any of it works, not evidence of benefit, and not a treatment recommendation. Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-04; the queries behind them are published with the dataset so that anyone can repeat the count.

Where this is actually studied

Counts of registered studies using Exosomes, condition by condition, from clinicaltrials.gov API v2 (snapshot 2026-08-29). This is what researchers chose to register — not a claim about how well any of it worked.

Stroke recovery accounts for 13% of all Exosomes studies in this dataset (11 of 84). A provider offering this cell type for a condition far down the list is working well outside where the research effort sits.

Compare all three cell families side by side in the cell type by condition map.

What to ask before agreeing to anything

1. Which parent cells, which passage, and which isolation method produced this preparation?
2. What characterisation is provided — particle size distribution, marker panel, purity — and against which MISEV criteria?
3. How is potency defined and measured, beyond particle count?
4. Under which legal authorisation is this being administered, given no approved product exists?

Sources behind the numbers on this page

• PubMed — Exosomes
• ClinicalTrials.gov — registered studies
• EMA — advanced therapy medicinal products
• FDA — cellular and gene therapy products

Study counts above are our own extraction from ClinicalTrials.gov; the links let you reproduce them. Not medical advice, and not an assessment of whether any treatment is appropriate for you.